Company Encyclopedia
View More
name
ASCLETIS-B
01672.HK
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne.
1.377 T
01672.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking40/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-12.77%D
    • Profit Margin-10937.77%E
    • Gross Margin11.19%E
  • Growth ScoreE
    • Revenue YoY-76.54%E
    • Net Profit YoY-0.19%C
    • Total Assets YoY-10.64%E
    • Net Assets YoY-12.74%E
  • Cash ScoreE
    • Cash Flow Margin-0.91%D
    • OCF YoY-76.54%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio6.46%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Assessing Ascletis Pharma (SEHK:1672) Valuation After New ASC37 Obesity Candidate Advances Toward FDA IND Filing

    Ascletis Pharma (SEHK:1672) has advanced its ASC37 obesity candidate towards an FDA IND filing by 2026, marking a significant R&D milestone. Despite a 663.58% one-year shareholder return, its Price to Book ratio of 6.4x suggests it's valued below analyst targets but above the Hong Kong biotech average. Investors face risks like clinical setbacks and commercialization delays. The article encourages personalized investment analysis and highlights other potential investment opportunities.

    Simplywall·
    HK
    01672
    +3.33%
    Simplywall·
    HK
    01672
    +3.33%

    Ascletis Pharma Files HKEX Disclosure on Repurchase of 1.62 Million Shares for HK$20.94 Million

    Ascletis Pharma Inc. has filed a disclosure with the Hong Kong Stock Exchange about repurchasing 1.62 million shares for HKD 20.94 million. The shares will be canceled.

    Reuters·
    HK
    01672
    +3.33%
    Reuters·
    HK
    01672
    +3.33%

    Hong Kong stock pharmaceutical stocks strengthened, with ASCLETIS-B rising over 9%, CLOVER BIO-B rising over 8%, WUXI BIO rising nearly 7%, and CARSGEN-B rising over 5%

    Wallstreetcn·
    HK
    02197
    +2.92%
    US
    WXXWY
    +7.08%
    HK
    02269
    -0.97%
    Wallstreetcn·
    HK
    02197
    +2.92%
    US
    WXXWY
    +7.08%
    HK
    02269
    -0.97%

    Ascletis To Submit IND To U.S. FDA For ASC37 Oral Tablets In 2nd Qtr Of 2026

    Ascletis Pharma Inc :EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION (IND) TO U.S. FDA FOR ASC37 ORAL TABLETS IN SECOND QUARTER OF 2026

    Reuters·
    HK
    01672
    +3.33%
    Reuters·
    HK
    01672
    +3.33%

    Ascletis Unveils Potent Oral Triple Agonist ASC37 for Obesity Treatment

    Ascletis Pharma Inc. has selected ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development targeting obesity treatment. ASC37 showed significantly greater potency in preclinical studies compared to retatrutide. The company plans to submit an IND application to the U.S. FDA by Q2 2026. This announcement precedes a conference call on December 1, 2025. The original content was published by Ascletis via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    01672
    +3.33%
    Reuters·
    HK
    01672
    +3.33%
    © 2025 Longbridge｜Disclaimer